Sign In
Buy NTLA
$14.75
+1.73 (+13.29%)
At Close: Jun 04, 2026
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07:30am, Monday, 06'th Jan 2025
CAMBRIDGE, Mass, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therap
Intellia Crashes 60% in a Year: How Should You Play the Stock?
02:00pm, Friday, 20'th Dec 2024
NTLA stock is down significantly in 2024 as investors are not pleased with the recent data from its in vivo CRISPR-based therapies. We advise prospective investors to stay on the sidelines for now.
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 03'rd Dec 2024
CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy
11:30am, Tuesday, 26'th Nov 2024
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating hereditary transthyretin (ATTR) amyloidosis with polyneuropathy.
CAMBRIDGE, Mass, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therap
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
08:30am, Friday, 22'nd Nov 2024
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
10:57pm, Monday, 18'th Nov 2024
Intellia initiated the Phase 3 HAELO trial for NTLA-2002, targeting lifelong control of hereditary angioedema (HAE) with a single-dose CRISPR-based therapy. Positive Phase 2 NTLA-2002 data showed most
CAMBRIDGE, Mass., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus
08:30am, Monday, 11'th Nov 2024
Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on the Q3 earnings call setting the stage for a modest rally. While last month'
3 Fast-Growing Stocks Analysts See Doubling in Price
07:16am, Monday, 11'th Nov 2024
Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside poten
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus
10:50am, Friday, 08'th Nov 2024
Intellia's third-quarter earnings and revenues surpass estimates. The company provides updates on its pipeline candidates.
Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript
02:49pm, Thursday, 07'th Nov 2024
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Lina Li - Senior Director of Investor Relations and Corporate Communication
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates
09:56am, Thursday, 07'th Nov 2024
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to loss of $1.38 per share a year ago.
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
07:30am, Thursday, 07'th Nov 2024
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?
09:45am, Wednesday, 06'th Nov 2024
There's nothing bearish at all about what it reported recently.
